Novo Nordisk A/S's shares have stalled recently, but this looks like a natural digestion of gains from prior years. Click for ...

Sen. Bernie Sanders has been probing the high prices that Novo charges for Ozempic and Wegovy. Yesterday, he share that ...

In 2023, Norditropin, manufactured by Novo Nordisk, led the growth hormone deficiency market with revenue of USD 1.6 billion, maintaining a significant market share. Norditropin is anticipated to ...

Novo Nordisk markets medications that target diabetes, obesity, growth disorders, hemophilia, and hormone replacement. All of Vertex's revenue (for now, at least) stems from its therapies that ...

The drug manufacturer has developed a pill that could bring about weight loss of as much as 13% in three months, according to ...

Novo Nordisk's growth slowed and valuation is high, making it not a buy at current prices despite its strong diabetes and ...

for two ailments specific to Hemophilia A and growth hormone disorder. “We need to build our employees here so that we can meet that growing patient demand in those areas,” said Gariepy. The West ...

Ozempic maker Novo Nordisk on Wednesday said data showed its ... Amycretin targets the same GLP-1 hormone as other weight loss and diabetes drugs like Novo’s Ozempic and Wegovy and Lilly ...

There are currently no pharmaceutical treatments approved for general obesity in under-12s — as opposed to that found with some rare genetic disorders — said Claudia Fox, a professor from University ...

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage ...